1. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.
3. Matsuyama M, Matsumura S, Nonaka M, et al. Pathophysiology of pulmonary nontuberculous mycobacterial (NTM) disease. Respir Investig 2023;61:135-148.
6. Stout JE, Koh WJ, Yew WW. Update on pulmonary disease due to non-tuberculous mycobacteria. Int J Infect Dis 2016;45:123-134.
7. van Ingen J, Bendien SA, de Lange WC, et al. Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands. Thorax 2009;64:502-506.
8. Koh WJ, Kwon OJ, Jeon K, et al. Clinical significance of nontuberculous mycobacteria isolated from respiratory specimens in Korea. Chest 2006;129:341-348.
9. Tateishi Y, Hirayama Y, Ozeki Y, et al. Virulence of Mycobacterium avium complex strains isolated from immunocompetent patients. Microb Pathog 2009;46:6-12.
10. Kikuchi T, Watanabe A, Gomi K, et al. Association between mycobacterial genotypes and disease progression in Mycobacterium avium pulmonary infection. Thorax 2009;64:901-907.
11. Falkinham JO. Ecology of nontuberculous mycobacteria: where do human infections come from? Semin Respir Crit Care Med 2013;34:95-102.
13. Kim Y, Yoon JH, Ryu J, et al. Gastroesophageal reflux disease increases susceptibility to nontuberculous mycobacterial pulmonary disease. Chest 2023;163:270-280.
14. Loebinger MR, Quint JK, van der Laan R, et al. Risk factors for nontuberculous mycobacterial pulmonary disease: a systematic literature review and meta-analysis. Chest 2023;164:1115-1124.
16. Song JH, Kim BS, Kwak N, Han K, Yim JJ. Impact of body mass index on development of nontuberculous mycobacterial pulmonary disease. Eur Respir J 2021;57:2000454.
18. Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax 2017;72:ii1-ii64.
19. Kang EY. Radiologic diagnosis of nontuberculous mycobacterial pulmonary disease. J Korean Soc Radiol 2021;82:838-850.
20. Han DW, Jo KW, Kim OH, Shim TS. Cavity formation and its predictors in noncavitary nodular bronchiectatic Mycobacterium avium complex pulmonary disease. Respir Med 2021;179:106340.
24. Fennelly KP, Ojano-Dirain C, Yang Q, et al. Biofilm formation by Mycobacterium abscessus in a lung cavity. Am J Respir Crit Care Med 2016;193:692-693.
29. Griffith DE, Aksamit TR. Diagnostic criteria and the decision to treat nontuberculous mycobacterial pulmonary disease. Clin Chest Med 2023;44:757-769.
30. Tomishima Y, Urayama KY, Kitamura A, et al. Bronchoscopy for the diagnosis of nontuberculous mycobacterial pulmonary disease: specificity and diagnostic yield in a retrospective cohort study. Respir Investig 2022;60:355-363.
33. Du Rand IA, Blaikley J, Booton R, et al. British Thoracic Society guideline for diagnostic flexible bronchoscopy in adults: accredited by NICE. Thorax 2013;68 Suppl 1:i1-i44.
34. Bringhurst J, Weber DJ, Miller MB, et al. A bronchoscopy-associated pseudo-outbreak of Mycobacterium mucogenicum traced to use of contaminated ice used for bronchoalveolar lavage. Infect Control Hosp Epidemiol 2020;41:124-126.
35. Clinical And Laboratory Standards Institute (CLSI). Performance standards for susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes. CLSI; 2018.
36. Hwang JA, Kim S, Jo KW, Shim TS. Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course. Eur Respir J 2017;49:1600537.
37. Kwon BS, Lee JH, Koh Y, et al. The natural history of noncavitary nodular bronchiectatic Mycobacterium avium complex lung disease. Respir Med 2019;150:45-50.
38. Moon SM, Jhun BW, Baek SY, et al. Long-term natural history of non-cavitary nodular bronchiectatic nontuberculous mycobacterial pulmonary disease. Respir Med 2019;151:1-7.
39. Im Y, Hwang NY, Kim K, Kim H, Kwon OJ, Jhun BW. Impact of time between diagnosis and treatment for nontuberculous mycobacterial pulmonary disease on culture conversion and all-cause mortality. Chest 2022;161:1192-1200.
40. Marmor M, Talbot EA, Cohen KA. Treatment of nontuberculous mycobacterial lung disease is complex; thus, shared decision making is critical. Ann Am Thorac Soc 2022;19:1265-1267.
41. Park HJ, Kim JY, Yim JJ, Kwak N. Prognostic serum biomarkers in non-tuberculous mycobacterial pulmonary disease. J Infect Chemother 2023;29:1005-1007.
42. Huang HL, Lee MR, Liu CJ, et al. Predictors of radiographic progression for NTM-pulmonary disease diagnosed by bronchoscopy. Respir Med 2020;161:105847.
44. Ito Y, Hirai T, Maekawa K, et al. Predictors of 5-year mortality in pulmonary Mycobacterium avium-intracellulare complex disease. Int J Tuberc Lung Dis 2012;16:408-414.
45. Jhun BW, Moon SM, Jeon K, et al. Prognostic factors associated with long-term mortality in 1445 patients with nontuberculous mycobacterial pulmonary disease: a 15-year follow-up study. Eur Respir J 2020;55:1900798.
46. Edwards BD, Brode SK, Mehrabi M, Marras TK. Time to positive culture detection predicts Mycobacterium avium pulmonary disease severity and treatment initiation. Ann Am Thorac Soc 2022;19:925-932.
47. Kim HJ, Kwak N, Hong H, et al. BACES score for predicting mortality in nontuberculous mycobacterial pulmonary disease. Am J Respir Crit Care Med 2021;203:230-236.
49. Yan M, Fraser B, McArthur E, Mehrabi M, Brode SK, Marras TK. External validation of the BACES Score in Canadian patients with nontuberculous mycobacterial pulmonary disease. Chest 2023;13:S0012-3692(23)05559-9.